These press releases are for business and financial media.
-
- 19 June 2007
- AstraZeneca Successfully Completes Acquisition of MedImmune View full press release
-
- 06 June 2007
- AstraZeneca CFO to join Goldman Sachs AstraZeneca PLC announces the resignation of its Chief Financial Officer, Jon Symonds, with effect from the end of July. Jon Symonds joined Zeneca in 1997 as CFO after 17 years at KPMG. Within months of joining, he was involved in the merger negotiations with Swedish pharmaceutical company, Astra. After completion of the merger in 1999, Jon was appointed as CFO for AstraZeneca PLC.
-
- 04 June 2007
- AstraZeneca Acquires Biologics Manufacturing Facility in Canada AstraZeneca today announced that it has acquired a biologics manufacturing facility in Montreal, Canada, from DSM Biologics Inc. The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group.
-
- 01 June 2007
- AstraZeneca’s Prilosec® Patents Upheld By Court AstraZeneca today announced a ruling by the US District Court for the Southern District of New York that found two Prilosec® (omeprazole) formulation patents valid and infringed by Impax Laboratories Inc. and Apotex Corp.
-
- 18 May 2007
- FDA Approves AstraZeneca’s Once-Daily SEROQUEL XR™ Extended-Release Tablets For The Treatment Of Schizophrenia AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients. The SEROQUEL XR development programme was based on the needs of patients and physicians for a wider choice of medicines that offer convenient once-daily dosing. With SEROQUEL XR patients can achieve a dose within the recommended range as early as the second day of treatment.
-
- 23 April 2007
- First quarter results 2007 “First quarter sales up 9 percent and Earnings per Share up 14 percent. On track to achieve full year financial targets.”
-
- 23 April 2007
- AstraZeneca announces decision to discontinue collaboration with AtheroGenics regarding AGI-1067 AstraZeneca today announced that it has decided to terminate the License and Collaboration Agreement with AtheroGenics, Inc. (Nasdaq: AGIX), regarding AGI-1067.
-
- 20 April 2007
- Senior Management Changes At AstraZeneca
-
- 17 April 2007
- Alistair Darling MP, Secretary of State for Trade and Industry, Celebrates ‘Golden Age’ of Science and Innovation at AstraZeneca’s Alderley Park Site Alistair Darling MP, Secretary of State for Trade and Industry, today visited AstraZeneca in Cheshire to launch the official celebration of Alderley Park’s 50th Anniversary.
-
- 25 March 2007
- First Study To Show Positive Benefit On Atherosclerosis For People With Early Signs Of Diseased Arteries AstraZeneca today announced that the METEOR clinical trial of CRESTOR is the first study to show a positive effect on atherosclerosis in people with early signs of carotid artery disease and at low risk of coronary heart disease (CHD).
-
- 23 March 2007
- AstraZeneca Names Shanghai Site As Initial Base for New Innovation Centre China AstraZeneca today announced Shanghai’s Zhangjiang Hi-Tech Park as the initial base for its new Innovation Centre China (ICC).
-
- 21 March 2007
- AstraZeneca Inaugurates State-of-the-Art Global Process R&D lab in Bangalore AstraZeneca today inaugurated a new state-of-the-art Process and Development (PR&D) laboratory next to its R&D centre in Bangalore, India.
-
- 19 March 2007
- Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint AstraZeneca today announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).
-
- 18 March 2007
- SEROQUEL® Sustained Release Schizophrenia Data presented at ECP Congress in Madrid AstraZeneca today announced clinical trial data for SEROQUEL® sustained release formulation (quetiapine fumarate sustained release), at the European Congress of Psychiatry (ECP) in Madrid. The data demonstrated that the SEROQUEL® sustained release formulation (quetiapine fumarate sustained release), administered once daily, significantly improved symptoms associated with schizophrenia (measured by PANSS) and increased the time to psychiatric relapse, when administered through a three-step dose initiation
-
- 01 March 2007
- AstraZeneca Issues 2006 Annual Report AstraZeneca today published its 2006 Annual Report and Form 20-F Information, its 2006 Annual Review and its 2006 Corporate Responsibility Summary Report. These documents are available on the company’s website, www.astrazeneca.com/annualreport .
-
- 22 February 2007
- AstraZeneca Announces Investment in $120m Laboratory for Process Research and Development at its Macclesfield Site, Cheshire, UK AstraZeneca is to invest $120 million in a new Process Research and Development (PR&D) Laboratory at its Macclesfield site, Cheshire, adding to the company’s significant investment in the UK over recent years.
-
- 15 February 2007
- AstraZeneca Wins Second Award for Investment in China AstraZeneca has won the 48 Club Group award for UK Outward Investor of the Year 2007 recognising the company’s considerable investment in China. The award was handed over at a ceremony at The Guildhall in London today.
-
- 01 February 2007
- Fourth Quarter and Full Year Results 2006 AstraZeneca PLC - Fourth Quarter and Full Year Results 2006
-
- 01 February 2007
- AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities AstraZeneca today announced an agreement to acquire Arrow Therapeutics Ltd., a privately owned UK biotechnology company, focused on the discovery and development of anti-viral therapies. The total share capital of Arrow Therapeutics will be purchased for $150m cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2007.
-
- 31 January 2007
- AstraZeneca and Palatin Technologies Announce Worldwide Collaboration to Discover, Develop and Commercialise Obesity Compounds AstraZeneca and Palatin Technologies (AMEX: PTN) today announced an exclusive global licensing and research collaboration agreement to discover, develop and commercialise small molecule compounds that target melanocortin receptors.
-
- 22 January 2007
- AstraZeneca Makes $100M Research Investment In Boston AstraZeneca today announced a $100m research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its R&D center near Boston, Massachusetts.
-
- 11 January 2007
- AstraZeneca and Bristol-Myers Squibb Announce Worldwide Collaboration To Develop And Commercialise Diabetes Compounds AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today announced a collaboration to develop and commercialise two investigational compounds being studied for the treatment of Type 2 diabetes. Both compounds were discovered by Bristol-Myers Squibb.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
